Phaseline

Companies › AbCellera Biologics

AbCellera Biologics: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 2 Phase 1; Genitourinary, Other; next expected readout Feb 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
ABCL635–Phase 1Vasomotor Symptoms Associated With MenopauseFeb 2027
ABCL575–Phase 1Healthy VolunteersApr 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07118891ABCL635Phase 1Vasomotor Symptoms Associated With MenopauseGenitourinaryFeb 2027
NCT07108894ABCL575Phase 1Healthy VolunteersOtherApr 2027

From the company's SEC filings

Cash and short-term investments of $764m on 2026-09-30; operating cash flow positive

Press releases filed as 8-K in the last year:

Specialist investors

Held by 2 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.